📰 Cell Type Specific Expression News
Cell Type Specific Expression News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Cell Type Specific Expression. Real-time updates on events, politics, business and more.
April 23, 2024
LEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a broad set
April 22, 2024
LEXINGTON, Mass., April 22, 2024 -- Voyager Therapeutics, Inc. , a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a broad set of data...
January 2, 2024
- Collaboration with gene therapy leader Novartis aims to discover and develop new approaches for Huntington’s disease and spinal muscular atrophy -
November 22, 2023
<p>To overcome both the risks of immune rejection and of potential tumor formation during cell and organ transplants, researchers Baoyang Hu and colleagues from the <a href="https://www.cas.cn/" target="_blank">Chinese Academy of Sciences</a>, Beijing, have genetically engineered stem cells so that liver cells obtained from them would be invisible to the immune system. At the same time, immature, potentially tumorigenic stem cells would still be attacked and...
April 19, 2023
Parkinson's disease is a progressive disorder that is caused by the degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells
April 19, 2023
Parkinsons disease is a progressive disorder that is caused by the degeneration of nerve cells in the part of the brain called the substantia nigra, which...
January 9, 2023
WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc. (NBIX) and Voyager Therapeutics Inc. (VYGR) said that they have collaborated to advance multiple gene therapies for the treatment of neurological
March 19, 2022
Voyager Therapeutics has promising technology. But the stock is very risky.
March 8, 2022
Voyager receives $54 million upfront with potential option exercise fees and milestone payments of up to $1.7 billion plus product sales-based royalties ...
March 8, 2022
08.03.2022 - Voyager receives $54 million upfront with potential option exercise fees and milestone payments of up to $1.7 billion plus product sales-based royalties Novartis receives target-specific access to Voyager’s novel TRACER AAV capsids for potential ... Seite 1